Examkin

Soru

Zorluk: KolayInfectious Diseases

An otherwise healthy 45-year-old woman receives treatment in the inpatient ward for an acute complicated urinary tract infection with associated bacteremia. At the time of admission two days ago, she presented with fever, chills, and costovertebral angle tenderness, prompting the initiation of empiric intravenous piperacillin-tazobactam. Today, she has been afebrile for the past 24 hours, her flank pain has nearly resolved, and she is tolerating a regular diet. Final culture results from both blood and urine demonstrate growth of *Escherichia coli*. The susceptibility report indicates resistance to ampicillin, but susceptibility to ceftriaxone, trimethoprim-sulfamethoxazole, levofloxacin, and piperacillin-tazobactam. Based on the culture results and the patient's clinical improvement, what is the most appropriate next step in management?

  1. A
    Maintain the current regimen of intravenous piperacillin-tazobactam
  2. B
    Escalate therapy to intravenous meropenem
  3. Transition to oral trimethoprim-sulfamethoxazoleCevap
  4. D
    Prescribe oral amoxicillin and discharge
  5. E
    Supplement the current regimen with intravenous gentamicin

Cevap

Transition to oral trimethoprim-sulfamethoxazole
The correct answer is to transition the patient to oral trimethoprim-sulfamethoxazole. The patient is clinically stable, afebrile, and tolerating an oral diet, which meets the criteria for transitioning from intravenous to oral antibiotics. Furthermore, proper antibiotic stewardship dictates de-escalating from broad-spectrum empiric coverage (like piperacillin-tazobactam) to a narrower-spectrum, targeted agent based on culture and susceptibility data. Trimethoprim-sulfamethoxazole has excellent oral bioavailability and the patient's isolate is explicitly susceptible to it.

Adım Adım Çözüm

1
Evaluate the patient's clinical status for transition to oral therapy.
The patient is afebrile, improving, and tolerating an oral diet.
Clinical stability and the ability to take medications by mouth are the primary indications for safely switching from intravenous to oral antibiotics.
2
Analyze the culture and susceptibility data to select a targeted antimicrobial agent.
The Escherichia coli isolate is susceptible to several narrower-spectrum agents, including trimethoprim-sulfamethoxazole.
Antimicrobial stewardship guidelines mandate de-escalating from broad-spectrum empiric therapy to the narrowest effective agent once sensitivities are known.
3
Select the most appropriate oral antibiotic for step-down therapy.
Oral trimethoprim-sulfamethoxazole is chosen over intravenous options.
It provides targeted coverage against the susceptible isolate and has excellent oral bioavailability, allowing for safe completion of the treatment course.

Anahtar Kavram

Antibiotic stewardship and de-escalation of antimicrobial therapy
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru